Search Our Site

Treatment for Rare Blood Clotting Disorder Shows Efficacy in Phase 3 Study

Treatment for Rare Blood Clotting Disorder Shows Efficacy in Phase 3 Study

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of... Read More »

Read More →

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of… Read More »

[...]

Read More

2018 Top 5 Lists

By Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies AMS has released its fifth annual top five list of researched specialty drugs and diagnoses this year’s list includes: 2018 Top 5 PredictRx Views 2018 Top 5 PredictDx Views 2017-18 Top 5 Increased PredictRx Views 2017-18 Top 5 Increased PredictDx Views As with... Read More »

Read More →

By Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies AMS has released its fifth annual top five list of researched specialty drugs and diagnoses this year’s list includes: 2018 Top 5 PredictRx Views 2018 Top 5 PredictDx Views 2017-18 Top 5 Increased PredictRx Views 2017-18 Top 5 Increased PredictDx Views As with… Read More »

[...]

Read More

Massachusetts Initiative Looks at Payment Plans for Novartis’ SMA Gene Therapy

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,... Read More »

Read More →

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,… Read More »

[...]

Read More

Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed... Read More »

Read More →

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed… Read More »

[...]

Read More

Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs

Louisiana will use the ‘Netflix’ model, with the goal of treating 10,000 people with hepatitis C in its Medicaid and prison population by 2020. Louisiana officials announced Thursday that their state would become the first to move forward with a new way to pay for expensive hepatitis C treatments, which could dramatically increase the number... Read More »

Read More →

Louisiana will use the ‘Netflix’ model, with the goal of treating 10,000 people with hepatitis C in its Medicaid and prison population by 2020. Louisiana officials announced Thursday that their state would become the first to move forward with a new way to pay for expensive hepatitis C treatments, which could dramatically increase the number… Read More »

[...]

Read More

“Christmas Berry” Plant Compound Could Fight Uveal Melanoma

A molecule derived from a type of primrose could prove to be a potent inhibitor of metastatic growth for a rare and aggressive cancer. Christmas berry plant (Ardisia crenata) PHILADELPHIA — Doctors diagnose about 2,000 adults with uveal melanoma, a cancer of the eye, every year. In half of cases, the disease metastasizes to the... Read More »

Read More →

A molecule derived from a type of primrose could prove to be a potent inhibitor of metastatic growth for a rare and aggressive cancer. Christmas berry plant (Ardisia crenata) PHILADELPHIA — Doctors diagnose about 2,000 adults with uveal melanoma, a cancer of the eye, every year. In half of cases, the disease metastasizes to the… Read More »

[...]

Read More

Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment

Hoping to earn its share of the $3.5 trillionhealth care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to do-it-yourself genetic tests and unapproved stem cell treatments. Spending on health care marketing nearly doubled from 1997 to 2016, soaring to at least $30 billion a... Read More »

Read More →

Hoping to earn its share of the $3.5 trillionhealth care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to do-it-yourself genetic tests and unapproved stem cell treatments. Spending on health care marketing nearly doubled from 1997 to 2016, soaring to at least $30 billion a… Read More »

[...]

Read More

FDA creating innovation office to speed drug development

The FDA is creating an office of drug development science to cut the cost of bringing new medicines to patients, BioCentury reports. Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs. FDA Commissioner Scott Gottlieb, M.D., is due to reveal the... Read More »

Read More →

The FDA is creating an office of drug development science to cut the cost of bringing new medicines to patients, BioCentury reports. Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs. FDA Commissioner Scott Gottlieb, M.D., is due to reveal the… Read More »

[...]

Read More

Drugmakers open new year with price increases on dozens of medicines

Dive Brief: Several major drugmakers, including Allergan, Bristol-Myers Squibb and Eli Lilly, increased prices on a number of their drugs Jan. 1, holding with typical industry practice despite continuing scrutiny of rising pharmaceutical costs. Relative to its pharma peers, Allergan moved most aggressively, upping the list price of Linzess, Lo Loestrin and 25 other medicines... Read More »

Read More →

Dive Brief: Several major drugmakers, including Allergan, Bristol-Myers Squibb and Eli Lilly, increased prices on a number of their drugs Jan. 1, holding with typical industry practice despite continuing scrutiny of rising pharmaceutical costs. Relative to its pharma peers, Allergan moved most aggressively, upping the list price of Linzess, Lo Loestrin and 25 other medicines… Read More »

[...]

Read More

CAR T therapies show durable responses, potential benefits from combinations

The dawn of regulator-approved chimeric antigen receptor (CAR) T-cell therapies, such as Kymriah (tisagenlecleucel, Novartis AG), have provided doctors with important new options for treating people with several types of aggressive blood cancers. But how long the new therapies can help and whether their costs can be made sustainable remain open questions. New research presented... Read More »

Read More →

The dawn of regulator-approved chimeric antigen receptor (CAR) T-cell therapies, such as Kymriah (tisagenlecleucel, Novartis AG), have provided doctors with important new options for treating people with several types of aggressive blood cancers. But how long the new therapies can help and whether their costs can be made sustainable remain open questions. New research presented… Read More »

[...]

Read More

Page 1 of 50

Categories
Archives